Canadian start-up Novobind Livestock Therapeutics has started raising investment to support the development of its nanobody-based biologics.
The firm’s platform produces nanobodies derived from the VHH domain of llama heavy chain-only antibodies for animal feed applications. The Vancouver-based company is working on nanobody-based biologics (called NBXs) designed to neutralize key pathogens affecting poultry and shrimp.
Download Article Below
Novobind_begins_fundraising_to_commercialize_its_nanobody_platform
.pdf
Download PDF • 165KB